In Vitro Efficacy Testing Services for Retinal Degeneration

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for retinal degeneration. Our services enable detailed assessment of drug candidates targeting key mechanisms implicated in retinal degeneration, including photoreceptor cell survival, inflammation, and oxidative stress. We focus on pivotal targets such as rhodopsin, retinal pigment epithelium (RPE) proteins, and signaling pathways involved in cell death and neuroprotection. Our assays can evaluate compound effects on pathological processes such as photoreceptor apoptosis, protein aggregation, and retinal cell viability.

Our in vitro efficacy testing services employ a range of advanced biochemical and cell-based assays tailored for retinal degeneration research. These include fluorescence-based, luminescence-based, and radioactivity assays to detect and quantify target engagement and biological activity. Each method is designed to provide sensitive, reproducible data on drug efficacy and mechanism of action.

Fluorescence resonance energy transfer (FRET) assay: Enables real-time monitoring of molecular interactions, such as protein-protein or protein-ligand binding, which are relevant for assessing therapeutic targeting in retinal degeneration pathways.

Fluorescent assay: Utilizes fluorescent probes to measure cellular events like viability, apoptosis, or oxidative stress, providing rapid and quantitative analysis of compound effects in retinal cells.

Luciferine/luciferase assay: Detects luciferase enzyme activity as a reporter for gene expression or cellular signaling, allowing sensitive measurement of pathway modulation by test compounds.

Radioactivity assay: Employs radioisotope-labeled substrates or ligands to quantify binding, uptake, or enzymatic activity, offering high sensitivity for low-abundance targets involved in retinal degeneration.

We measure a comprehensive set of pharmacological parameters to assess compound potency, efficacy, and binding characteristics. These parameters are essential for ranking candidate molecules and optimizing lead selection in drug development pipelines. Accurate measurement of these values supports informed decision-making and risk reduction in preclinical research.

EC-50: The concentration of a compound that achieves 50% of its maximal effect, indicating functional potency in the relevant assay system.

IC-50: The concentration required to inhibit a specific biological process or enzyme by 50%, used to evaluate inhibitory strength against disease-related targets.

Kd: The equilibrium dissociation constant reflecting the affinity between a drug and its target, critical for understanding binding efficiency and selectivity.

MIC: The minimum inhibitory concentration necessary to prevent cellular or microbial activity, important for assessing efficacy in anti-infective or cytoprotective contexts.

Recommended In Vitro Efficacy Tests

Glycogen Synthase Kinase 3 Beta

Our Glycogen Synthase Kinase 3 Beta (GSK3β) testing service supports retinal degeneration drug development by evaluating GSK3β’s role in neurodegenerative pathways. This testing is crucial for identifying compounds that modulate GSK3β activity, a key factor in retinal cell survival. We utilize FRET and luciferin/luciferase assays to measure compound efficacy, providing essential parameters such as Minimum Inhibitory Concentration (MIC) and IC50 for precise drug candidate assessment.

Htra Serine Peptidase 1

Htra Serine Peptidase 1 is implicated in retinal degeneration by promoting proteolytic stress and cell death in retinal tissue. Testing Htra1 activity is crucial for evaluating potential therapeutic inhibitors in drug development. Our service utilizes a sensitive fluorescent assay to measure enzyme activity, providing accurate IC-50 values for compound efficacy assessment. This enables rapid and reliable screening of drug candidates targeting Htra1-mediated retinal degeneration.

Retinoid Isomerohydrolase Rpe65

Retinoid Isomerohydrolase Rpe65 is essential for the visual cycle; its dysfunction contributes to retinal degeneration. Rpe65 testing is crucial for screening drug candidates targeting retinal diseases. Our service utilizes both radioactivity and fluorescent assays to evaluate compound interactions with Rpe65, providing key parameters such as IC-50 (inhibitory concentration) and Kd (binding affinity) to guide drug development decisions efficiently and accurately.

Rhodopsin

Rhodopsin is a key photoreceptor protein implicated in retinal degeneration, making it a vital target for drug development. Our Rhodopsin testing service uses a sensitive fluorescent assay to evaluate compound interactions, specifically measuring the half-maximal effective concentration (EC-50). This testing is essential for screening drug candidates, enabling the identification of molecules that modulate Rhodopsin activity and potentially slow or prevent retinal degeneration.